Építés alatt – nem éles oldal
Belépés
LeállítvaFázis nélkül

Remote Monitoring of the Diabetic Foot to Prevent Re-Ulceration

A legfontosabb adatok

Ki végzi
Bluedrop Medical Limited
Hol
Durham (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Leállítva
Résztvevők
26 fő vett részt
Kezdés
2024. jan. 22.
Befejezés
2024. szept. 18.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
A vizsgált kezelések
  • Bluedrop Monitoring Service (BMS)
A regiszteradat frissítve
2024. október 17.
Miért állt le
Unsustainable recruitment rate - too slow to enroll participants

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 23 feltétel megnézéseKevesebb

Ki vehet részt

  • Understanding of the study procedures and conditions of the protocol and agreement to participate in the study by providing consent prior to any study-specific procedures
  • Male or female patients 18 years or older
  • Diagnosis of type 1 or type 2 diabetes mellitus more than 3 months prior to the Screening Visit
  • History of healed diabetic foot ulcer(s), present for at least 2 weeks and healed within 2-24 months prior to screening
  • Confirmation of presence of peripheral neuropathy with loss of protective sensation (documented in medical records or certain ICD-10 codes for care of patients with diabetes and loss of protective sensation)
  • Patient has signed up for and provided or will provide consent to review of medical records available via the Pluto platform
  • Access to internet service at the site of device use or willing to use a 4G router provided by the Sponsor
  • Access to cell phone on which they can receive study communications
  • Has a healthcare provider who is confirmed to be their point of contact for foot care or injuries and this HCP uses an EHR that is compatible with Pluto
  • English speaking

Ki nem vehet részt

  • Active foot infection or gangrene
  • Any history of major or minor lower limb amputation of more than 3 toes. NOTE: the hallux toe must be present on both feet to be eligible
  • Critical limb ischemia as evidenced by rest pain. NOTE: a healed ulcer indicates adequate perfusion and qualifies for the study
  • Any mental health disorder, psychiatric disorder, or alcohol or drug abuse history such that, in the opinion of the investigator, the patient is unreliable as a study participant
  • End-stage kidney disease (estimated GFR <15 mL/min/1.73 m2, and/or receiving renal replacement therapy)
  • Patients with active foot ulcers or other open foot lesions
  • Weight, when fully clothed, of greater than 150 kg
  • Active Charcot arthropathy defined as the phase where the foot is undergoing collapse
  • Known pregnancy at the time of enrollment.*
  • Any travel plans expected to result in an interruption of BMS use for greater than 30 consecutive days
  • Unable to identify and/or return to a usual care provider for foot care for the duration of the study
  • Unable or unwilling to be enrolled in the Pluto unified medical records system
  • Other issue that, at the discretion of the PI, renders the participant ineligible for participation. This includes inability to use the BMS for at least 3 days per week; Participants who become pregnant during the study will not be removed. Pregnancy will be noted in their mobile application profile and their participation in the study will be closely monitored

Helyszínek itt: Egyesült Államok

  • Duke Clinical Research InstituteDurham, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to understand the effects of the Bluedrop Monitoring System (BMS) on the development of diabetic foot ulcers.

A teljes eredeti leírásKevesebb

All Participants in this study will continue with their normal foot care and complete surveys with questions about their foot health every three months.

Participants selected to receive the Bluedrop Monitoring System (BMS) will place it in their home and stand on it once a day for 12 months. Participants will also need to answer questions about their general foot health and, if using the system, their experience using the device and monitoring service.

A vizsgálat 2 csoportja

  • Use of Bluedrop Monitoring ServiceA vizsgált kezelés

    The BMS is made up of the Delta Foot Scanner (DFS) device, its accompanying Sentinel Review Interface (SRI) software and a Bluedrop virtual monitoring service. The DFS is intended to be used for 30 seconds, once per day, by a person in their home. It is important that while using the device that the participant continues with their routine foot care as recommended by their doctor.

    Kezelés: Bluedrop Monitoring Service (BMS)

  • Standard of careNincs vizsgálati kezelés, összehasonlításként

    Participants continue with routine foot care as recommended by their doctor

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Remote Use of Thermovisual Monitoring to Reduce the RAte of Re-Ulceration in PatientS at Risk of RecurrenT Diabetic Foot UlcERs
A regiszteradat frissítve
2024. október 17.